Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Targeting Serotonin Transporters in the Treatment of Juvenile and Adolescent Depression.

Bowman MA, Daws LC.

Front Neurosci. 2019 Feb 27;13:156. doi: 10.3389/fnins.2019.00156. eCollection 2019.

2.

Neuroinflammation Contributes to High Salt Intake-Augmented Neuronal Activation and Active Coping Responses to Acute Stress.

Gilman TL, Mitchell NC, Daws LC, Toney GM.

Int J Neuropsychopharmacol. 2019 Feb 1;22(2):137-142. doi: 10.1093/ijnp/pyy099.

3.

Comparative analysis of novel decynium-22 analogs to inhibit transport by the low-affinity, high-capacity monoamine transporters, organic cation transporters 2 and 3, and plasma membrane monoamine transporter.

Fraser-Spears R, Krause-Heuer AM, Basiouny M, Mayer FP, Manishimwe R, Wyatt NA, Dobrowolski JC, Roberts MP, Greguric I, Kumar N, Koek W, Sitte HH, Callaghan PD, Fraser BH, Daws LC.

Eur J Pharmacol. 2019 Jan 5;842:351-364. doi: 10.1016/j.ejphar.2018.10.028. Epub 2018 Oct 25.

PMID:
30473490
4.

Prenatal metformin exposure or organic cation transporter 3 knock-out curbs social interaction preference in male mice.

Garbarino VR, Santos TA, Nelson AR, Zhang WQ, Smolik CM, Javors MA, Daws LC, Gould GG.

Pharmacol Res. 2019 Feb;140:21-32. doi: 10.1016/j.phrs.2018.11.013. Epub 2018 Nov 10.

PMID:
30423430
5.

"Polytox" synthetic cathinone abuse: A potential role for organic cation transporter 3 in combined cathinone-induced efflux.

Mayer FP, Schmid D, Holy M, Daws LC, Sitte HH.

Neurochem Int. 2019 Feb;123:7-12. doi: 10.1016/j.neuint.2018.09.008. Epub 2018 Sep 21.

6.

Extreme enhancement or depletion of serotonin transporter function and serotonin availability in autism spectrum disorder.

Garbarino VR, Gilman TL, Daws LC, Gould GG.

Pharmacol Res. 2019 Feb;140:85-99. doi: 10.1016/j.phrs.2018.07.010. Epub 2018 Jul 24. Review.

PMID:
30009933
7.

Constitutive plasma membrane monoamine transporter (PMAT, Slc29a4) deficiency subtly affects anxiety-like and coping behaviours.

Gilman TL, George CM, Vitela M, Herrera-Rosales M, Basiouny MS, Koek W, Daws LC.

Eur J Neurosci. 2018 May 24. doi: 10.1111/ejn.13968. [Epub ahead of print]

PMID:
29797618
8.

An unsuspected role for organic cation transporter 3 in the actions of amphetamine.

Mayer FP, Schmid D, Owens WA, Gould GG, Apuschkin M, Kudlacek O, Salzer I, Boehm S, Chiba P, Williams PH, Wu HH, Gether U, Koek W, Daws LC, Sitte HH.

Neuropsychopharmacology. 2018 Nov;43(12):2408-2417. doi: 10.1038/s41386-018-0053-5. Epub 2018 Apr 6.

9.

High salt intake enhances swim stress-induced PVN vasopressin cell activation and active stress coping.

Mitchell NC, Gilman TL, Daws LC, Toney GM.

Psychoneuroendocrinology. 2018 Jul;93:29-38. doi: 10.1016/j.psyneuen.2018.04.003. Epub 2018 Apr 6.

PMID:
29684712
10.

Effects of the antidepressants desipramine and fluvoxamine on latency to immobility and duration of immobility in the forced swim test in adult male C57BL/6J mice.

Koek W, Sandoval TL, Daws LC.

Behav Pharmacol. 2018 Aug;29(5):453-456. doi: 10.1097/FBP.0000000000000371.

PMID:
29200003
11.
12.

Extending the family: Roles for uptake2 transporters in regulation of monoaminergic signaling.

Gasser PJ, Daws LC.

J Chem Neuroanat. 2017 Oct;83-84:107-108. doi: 10.1016/j.jchemneu.2017.07.009. Epub 2017 Jul 28. No abstract available.

PMID:
28757392
13.

Editorial for the special issue: Monoamine transporters in health and disease.

Gasser PJ, Daws LC.

J Chem Neuroanat. 2017 Oct;83-84:1-2. doi: 10.1016/j.jchemneu.2017.07.008. Epub 2017 Jul 27. No abstract available.

PMID:
28755997
14.

Evaluation of the antidepressant therapeutic potential of isocyanine and pseudoisocyanine analogues of the organic cation decynium-22.

Krause-Heuer AM, Fraser-Spears R, Dobrowolski JC, Ashford ME, Wyatt NA, Roberts MP, Gould GG, Cheah WC, Ng CKL, Bhadbhade M, Zhang B, Greguric I, Wheate NJ, Kumar N, Koek W, Callaghan PD, Daws LC, Fraser BH.

Eur J Med Chem. 2017 Sep 8;137:476-487. doi: 10.1016/j.ejmech.2017.06.011. Epub 2017 Jun 7.

15.

Ca2+ dependent surface trafficking of norepinephrine transporters depends on threonine 30 and Ca2+ calmodulin kinases.

Sung U, Binda F, Savchenko V, Owens WA, Daws LC.

J Chem Neuroanat. 2017 Oct;83-84:19-35. doi: 10.1016/j.jchemneu.2016.12.003. Epub 2016 Dec 23.

16.

Ontogeny of Norepinephrine Transporter Expression and Antidepressant-Like Response to Desipramine in Wild-Type and Serotonin Transporter Mutant Mice.

Mitchell NC, Bowman MA, Gould GG, Koek W, Daws LC.

J Pharmacol Exp Ther. 2017 Jan;360(1):84-94. Epub 2016 Nov 9.

17.

Ontogeny of SERT Expression and Antidepressant-like Response to Escitalopram in Wild-Type and SERT Mutant Mice.

Mitchell NC, Gould GG, Koek W, Daws LC.

J Pharmacol Exp Ther. 2016 Aug;358(2):271-81. doi: 10.1124/jpet.116.233338. Epub 2016 Jun 10.

18.

Antidepressant-like effects and basal immobility depend on age and serotonin transporter genotype.

Mitchell NC, Koek W, Daws LC.

Genes Brain Behav. 2015 Sep;14(7):543-549. doi: 10.1111/gbb.12238.

19.

Eating high fat chow decreases dopamine clearance in adolescent and adult male rats but selectively enhances the locomotor stimulating effects of cocaine in adolescents.

Baladi MG, Horton RE, Owens WA, Daws LC, France CP.

Int J Neuropsychopharmacol. 2015 Mar 24;18(7):pyv024. doi: 10.1093/ijnp/pyv024.

20.

Acute dietary tryptophan manipulation differentially alters social behavior, brain serotonin and plasma corticosterone in three inbred mouse strains.

Zhang WQ, Smolik CM, Barba-Escobedo PA, Gamez M, Sanchez JJ, Javors MA, Daws LC, Gould GG.

Neuropharmacology. 2015 Mar;90:1-8. doi: 10.1016/j.neuropharm.2014.10.024. Epub 2014 Nov 4.

21.

Ethanol effects on multiple fixed-interval, fixed-ratio responding in mice with deletions of the serotonin transporter gene.

Lamb RJ, Pinkston JW, Daws LC.

Behav Pharmacol. 2014 Feb;25(1):92-5. doi: 10.1097/FBP.0000000000000011.

22.

5-HT1B receptor modulation of the serotonin transporter in vivo: studies using KO mice.

Montañez S, Munn JL, Owens WA, Horton RE, Daws LC.

Neurochem Int. 2014 Jul;73:127-31. doi: 10.1016/j.neuint.2013.11.004. Epub 2013 Nov 15.

23.

Antidepressant-like drug effects in juvenile and adolescent mice in the tail suspension test: Relationship with hippocampal serotonin and norepinephrine transporter expression and function.

Mitchell NC, Gould GG, Smolik CM, Koek W, Daws LC.

Front Pharmacol. 2013 Oct 28;4:131. doi: 10.3389/fphar.2013.00131. eCollection 2013.

24.

Catecholamine/Serotonin interactions: systems thinking for brain function and disease.

Hensler JG, Artigas F, Bortolozzi A, Daws LC, De Deurwaerdère P, Milan L, Navailles S, Koek W.

Adv Pharmacol. 2013;68:167-97. doi: 10.1016/B978-0-12-411512-5.00009-9. Review.

25.

Ethanol self-administration in serotonin transporter knockout mice: unconstrained demand and elasticity.

Lamb RJ, Daws LC.

Genes Brain Behav. 2013 Oct;12(7):741-7. doi: 10.1111/gbb.12068. Epub 2013 Aug 23.

26.

Membrane-permeable C-terminal dopamine transporter peptides attenuate amphetamine-evoked dopamine release.

Rickhag M, Owens WA, Winkler MT, Strandfelt KN, Rathje M, Sørensen G, Andresen B, Madsen KL, Jørgensen TN, Wörtwein G, Woldbye DP, Sitte H, Daws LC, Gether U.

J Biol Chem. 2013 Sep 20;288(38):27534-44. doi: 10.1074/jbc.M112.441295. Epub 2013 Jul 24.

27.

Decynium-22 enhances SSRI-induced antidepressant-like effects in mice: uncovering novel targets to treat depression.

Horton RE, Apple DM, Owens WA, Baganz NL, Cano S, Mitchell NC, Vitela M, Gould GG, Koek W, Daws LC.

J Neurosci. 2013 Jun 19;33(25):10534-43. doi: 10.1523/JNEUROSCI.5687-11.2013.

28.

Inhibition of dopamine transporter activity by G protein βγ subunits.

Garcia-Olivares J, Torres-Salazar D, Owens WA, Baust T, Siderovski DP, Amara SG, Zhu J, Daws LC, Torres GE.

PLoS One. 2013;8(3):e59788. doi: 10.1371/journal.pone.0059788. Epub 2013 Mar 26.

29.

Revisiting serotonin reuptake inhibitors and the therapeutic potential of "uptake-2" in psychiatric disorders.

Daws LC, Koek W, Mitchell NC.

ACS Chem Neurosci. 2013 Jan 16;4(1):16-21. doi: 10.1021/cn3001872.

30.

What's old is new.

Andrews AM, Daws LC.

ACS Chem Neurosci. 2013 Jan 16;4(1):1-2. doi: 10.1021/cn300229z. No abstract available.

31.

You are what you eat: influence of type and amount of food consumed on central dopamine systems and the behavioral effects of direct- and indirect-acting dopamine receptor agonists.

Baladi MG, Daws LC, France CP.

Neuropharmacology. 2012 Jul;63(1):76-86. doi: 10.1016/j.neuropharm.2012.02.005. Epub 2012 Feb 23. Review.

32.

Autism gene variant causes hyperserotonemia, serotonin receptor hypersensitivity, social impairment and repetitive behavior.

Veenstra-VanderWeele J, Muller CL, Iwamoto H, Sauer JE, Owens WA, Shah CR, Cohen J, Mannangatti P, Jessen T, Thompson BJ, Ye R, Kerr TM, Carneiro AM, Crawley JN, Sanders-Bush E, McMahon DG, Ramamoorthy S, Daws LC, Sutcliffe JS, Blakely RD.

Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5469-74. doi: 10.1073/pnas.1112345109. Epub 2012 Mar 19.

33.

Rescue of dopamine transporter function in hypoinsulinemic rats by a D2 receptor-ERK-dependent mechanism.

Owens WA, Williams JM, Saunders C, Avison MJ, Galli A, Daws LC.

J Neurosci. 2012 Feb 22;32(8):2637-47. doi: 10.1523/JNEUROSCI.3759-11.2012.

34.

Impaired striatal Akt signaling disrupts dopamine homeostasis and increases feeding.

Speed N, Saunders C, Davis AR, Owens WA, Matthies HJ, Saadat S, Kennedy JP, Vaughan RA, Neve RL, Lindsley CW, Russo SJ, Daws LC, Niswender KD, Galli A.

PLoS One. 2011;6(9):e25169. doi: 10.1371/journal.pone.0025169. Epub 2011 Sep 28.

35.

Ontogeny and regulation of the serotonin transporter: providing insights into human disorders.

Daws LC, Gould GG.

Pharmacol Ther. 2011 Jul;131(1):61-79. doi: 10.1016/j.pharmthera.2011.03.013. Epub 2011 Apr 5. Review.

36.

Insulin signaling and addiction.

Daws LC, Avison MJ, Robertson SD, Niswender KD, Galli A, Saunders C.

Neuropharmacology. 2011 Dec;61(7):1123-8. doi: 10.1016/j.neuropharm.2011.02.028. Epub 2011 Mar 21. Review.

37.

Transgenic elimination of high-affinity antidepressant and cocaine sensitivity in the presynaptic serotonin transporter.

Thompson BJ, Jessen T, Henry LK, Field JR, Gamble KL, Gresch PJ, Carneiro AM, Horton RE, Chisnell PJ, Belova Y, McMahon DG, Daws LC, Blakely RD.

Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3785-90. doi: 10.1073/pnas.1011920108. Epub 2011 Jan 31. Erratum in: Proc Natl Acad Sci U S A. 2011 Apr 19;108(16):6689.

38.

High-Speed Chronoamperometry to Study Kinetics and Mechanisms for Serotonin Clearance In Vivo.

Daws LC, Toney GM.

In: Michael AC, Borland LM, editors. Electrochemical Methods for Neuroscience. Boca Raton (FL): CRC Press/Taylor & Francis; 2007. Chapter 5.

39.

Insulin regulation of monoamine signaling: pathway to obesity.

Niswender KD, Daws LC, Avison MJ, Galli A.

Neuropsychopharmacology. 2011 Jan;36(1):359-60. doi: 10.1038/npp.2010.167. No abstract available.

40.

Density and function of central serotonin (5-HT) transporters, 5-HT1A and 5-HT2A receptors, and effects of their targeting on BTBR T+tf/J mouse social behavior.

Gould GG, Hensler JG, Burke TF, Benno RH, Onaivi ES, Daws LC.

J Neurochem. 2011 Jan;116(2):291-303. doi: 10.1111/j.1471-4159.2010.07104.x. Epub 2010 Dec 2.

41.

Repeated swim impairs serotonin clearance via a corticosterone-sensitive mechanism: organic cation transporter 3, the smoking gun.

Baganz N, Horton R, Martin K, Holmes A, Daws LC.

J Neurosci. 2010 Nov 10;30(45):15185-95. doi: 10.1523/JNEUROSCI.2740-10.2010.

42.

Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters.

Zhu CB, Lindler KM, Owens AW, Daws LC, Blakely RD, Hewlett WA.

Neuropsychopharmacology. 2010 Dec;35(13):2510-20. doi: 10.1038/npp.2010.116. Epub 2010 Sep 8.

43.

Insulin reveals Akt signaling as a novel regulator of norepinephrine transporter trafficking and norepinephrine homeostasis.

Robertson SD, Matthies HJ, Owens WA, Sathananthan V, Christianson NS, Kennedy JP, Lindsley CW, Daws LC, Galli A.

J Neurosci. 2010 Aug 25;30(34):11305-16. doi: 10.1523/JNEUROSCI.0126-10.2010.

44.

Dysregulation of the norepinephrine transporter sustains cortical hypodopaminergia and schizophrenia-like behaviors in neuronal rictor null mice.

Siuta MA, Robertson SD, Kocalis H, Saunders C, Gresch PJ, Khatri V, Shiota C, Kennedy JP, Lindsley CW, Daws LC, Polley DB, Veenstra-Vanderweele J, Stanwood GD, Magnuson MA, Niswender KD, Galli A.

PLoS Biol. 2010 Jun 8;8(6):e1000393. doi: 10.1371/journal.pbio.1000393.

45.

Reduced effectiveness of escitalopram in the forced swimming test is associated with increased serotonin clearance rate in food-restricted rats.

France CP, Li JX, Owens WA, Koek W, Toney GM, Daws LC.

Int J Neuropsychopharmacol. 2009 Jul;12(6):731-6. doi: 10.1017/S1461145709000418. Epub 2009 May 7.

46.

Organic cation transporter 3: Keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice.

Baganz NL, Horton RE, Calderon AS, Owens WA, Munn JL, Watts LT, Koldzic-Zivanovic N, Jeske NA, Koek W, Toney GM, Daws LC.

Proc Natl Acad Sci U S A. 2008 Dec 2;105(48):18976-81. doi: 10.1073/pnas.0800466105. Epub 2008 Nov 24.

47.

Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy.

Daws LC.

Pharmacol Ther. 2009 Jan;121(1):89-99. doi: 10.1016/j.pharmthera.2008.10.004. Epub 2008 Oct 29. Review.

48.

Feeding conditions differentially affect the neurochemical and behavioral effects of dopaminergic drugs in male rats.

Sevak RJ, Koek W, Owens WA, Galli A, Daws LC, France CP.

Eur J Pharmacol. 2008 Sep 11;592(1-3):109-15. doi: 10.1016/j.ejphar.2008.07.002. Epub 2008 Jul 10.

49.

Behavioral effects of amphetamine in streptozotocin-treated rats.

Sevak RJ, Koek W, Daws LC, Owens WA, Galli A, France CP.

Eur J Pharmacol. 2008 Feb 26;581(1-2):105-12. Epub 2007 Nov 28.

50.

Hypoinsulinemia regulates amphetamine-induced reverse transport of dopamine.

Williams JM, Owens WA, Turner GH, Saunders C, Dipace C, Blakely RD, France CP, Gore JC, Daws LC, Avison MJ, Galli A.

PLoS Biol. 2007 Oct 16;5(10):e274.

Supplemental Content

Support Center